My notes from the report -
(1) Company ran at breakeven during the second half with almost all profit made during the first half of FY2016.
(2) Human Healthcare now doing revenue per year $12.4M. In FY2013 this was $9.1M. Next year if the company does $13.5M this would represent a 50% increase in four years, which would be a great achievement.
(3) Average currency for H1 and H2 FY2016 was 72.3c and 73.4c AUD - USD. This was well below the previous year and a big contributor towards the lower gross profits as a percentage of sales.
(4) Based on Analytica’s annual report, sales of the FirstFlow and Tuta burettes with MediFlush increased by 17% YoY. Royalties to Analytica were $7,271 versus $6,228 the previous year.
If we assumed royalties to Analytica at 5% this implies the company is now doing $150K of sales for Analytica technology.
(5) Company seems to have stepped up sales efforts a gear in FY2015 with an increase in the travel and marketing expenses versus the previous year.
(6) Spreadsheet showing the separated figures last four half years is below. Currency analysis for the half years is from http://www.x-rates.com.
Sydney - the company is normally good at responding to shareholders (and potential shareholders). If you're still amenable, send your details across to [email protected] I will pass your details on to the company and ask them to contact you. Note this email address will expire in 48 hours.
MLA Price at posting:
4.9¢ Sentiment: Buy Disclosure: Held
